CR20180231A - Composiciones y métodos para ionhibir la expresión génica del lpa - Google Patents

Composiciones y métodos para ionhibir la expresión génica del lpa

Info

Publication number
CR20180231A
CR20180231A CR20180231A CR20180231A CR20180231A CR 20180231 A CR20180231 A CR 20180231A CR 20180231 A CR20180231 A CR 20180231A CR 20180231 A CR20180231 A CR 20180231A CR 20180231 A CR20180231 A CR 20180231A
Authority
CR
Costa Rica
Prior art keywords
lpa
gene expression
agents
compositions
ionhibit
Prior art date
Application number
CR20180231A
Other languages
English (en)
Inventor
Lauren J ; Almeida
Aaron; Almeida
David L Lewis
Tao; Pei
Zhen; Li
Vladimir S ; Trubetskoy
Stacey; Melquist
David B ; Rozema
Steven Kanner
Darren H; Wakefield
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of CR20180231A publication Critical patent/CR20180231A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3517Marker; Tag
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen los agentes de interferencia de ARN (ARNi) y los conjugados de los agentes ARNi para inhibir la expresión del gen LPA (apo(a)). También se describen composiciones farmacéuticas que comprenden uno o más agentes de ARNi de LPA opcionalmente con uno o más agentes terapéuticos. La entrega de los agentes de ARNi de LPA descritos a las células hepáticas in vivo proporciona la inhibición de la expresión del gen LPA y el tratamiento de enfermedades cardiovasculares y cardiovasculares relacionadas.
CR20180231A 2015-10-01 2016-09-30 Composiciones y métodos para ionhibir la expresión génica del lpa CR20180231A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US201662383221P 2016-09-02 2016-09-02
PCT/US2016/054729 WO2017059223A2 (en) 2015-10-01 2016-09-30 Compositions and methods for inhibiting gene expression of lpa

Publications (1)

Publication Number Publication Date
CR20180231A true CR20180231A (es) 2018-05-31

Family

ID=58424351

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180231A CR20180231A (es) 2015-10-01 2016-09-30 Composiciones y métodos para ionhibir la expresión génica del lpa

Country Status (37)

Country Link
US (3) US9932586B2 (es)
EP (2) EP4029941A1 (es)
JP (4) JP6991966B2 (es)
KR (1) KR20180052703A (es)
CN (1) CN108368506A (es)
AU (2) AU2016331084B2 (es)
BR (1) BR112018006489A2 (es)
CA (1) CA3000397A1 (es)
CL (1) CL2018000803A1 (es)
CO (1) CO2018003678A2 (es)
CR (1) CR20180231A (es)
CY (1) CY1125263T1 (es)
DK (1) DK3356529T3 (es)
EA (1) EA038478B1 (es)
ES (1) ES2896298T3 (es)
HK (1) HK1259063A1 (es)
HR (1) HRP20211410T1 (es)
HU (1) HUE055942T2 (es)
IL (3) IL300438A (es)
JO (2) JOP20210043A1 (es)
LT (1) LT3356529T (es)
MA (1) MA43347B1 (es)
MX (2) MX2018003833A (es)
MY (1) MY195796A (es)
PE (1) PE20181139A1 (es)
PH (1) PH12018500713A1 (es)
PL (1) PL3356529T3 (es)
PT (1) PT3356529T (es)
RS (1) RS62523B1 (es)
SG (1) SG10202008530TA (es)
SI (1) SI3356529T1 (es)
TN (1) TN2018000094A1 (es)
TW (2) TWI836693B (es)
UA (1) UA121998C2 (es)
UY (1) UY36926A (es)
WO (1) WO2017059223A2 (es)
ZA (1) ZA202106265B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
TWI783434B (zh) * 2016-03-07 2022-11-11 美商愛羅海德製藥公司 治療性化合物之標靶性配體
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
LT3607069T (lt) 2017-04-05 2023-01-10 Silence Therapeutics Gmbh Produktai ir kompozicijos
US10590416B2 (en) * 2017-07-06 2020-03-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
KR20200044013A (ko) * 2017-09-11 2020-04-28 애로우헤드 파마슈티컬스 인코포레이티드 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
TN2020000038A1 (en) * 2017-09-14 2021-10-04 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
CA3079413A1 (en) * 2017-10-17 2019-04-25 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of asialoglycoprotein receptor 1
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
EP3710586B1 (en) * 2017-11-13 2022-11-23 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of lpa in a cell
SG11202101698WA (en) * 2018-09-19 2021-04-29 Arrowhead Pharmaceuticals Inc Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use
FI3880818T3 (fi) * 2018-11-13 2022-12-15 Nukleiinihappoja LPA:n ekspression inhiboimiseksi solussa
EP4073252A1 (en) 2019-12-09 2022-10-19 Amgen Inc. Rnai constructs and methods for inhibiting lpa expression
BR112023001957A2 (pt) 2020-08-05 2023-04-25 Dicerna Pharmaceuticals Inc Composições e métodos para inibir expressão de lpa
CN116490195A (zh) * 2020-10-16 2023-07-25 赛诺菲 用于抑制脂蛋白(a)的RNA组合物和方法
MX2023005198A (es) 2020-11-05 2023-05-16 Amgen Inc Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa.
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
EP4237561A1 (en) 2020-12-23 2023-09-06 Argonaute Rna Limited Treatment of cardiovascular disease
EP4355756A1 (en) 2021-06-18 2024-04-24 Hongene Biotech Corporation Functionalized n-acetylgalactosamine nucleosides
WO2023034719A1 (en) 2021-08-30 2023-03-09 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2023041508A2 (en) 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
KR20240056619A (ko) * 2021-09-18 2024-04-30 제노바 테라퓨틱스 컴퍼니 리미티드 Lpa 억제제 및 이의 용도
US11993626B2 (en) 2021-12-15 2024-05-28 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2024032681A1 (zh) * 2022-08-11 2024-02-15 益杰立科(上海)生物科技有限公司 一种表观编辑靶点的方法及用途
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
ES2728168T3 (es) * 2000-12-01 2019-10-22 Max Planck Gesellschaft Moléculas pequeñas de ARN que median en la interferencia de ARN
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
JP2006523209A (ja) 2003-03-12 2006-10-12 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ アペリン組成物によって血管新生を調節するための方法
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
WO2008022309A2 (en) * 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
AU2009336191B2 (en) 2008-12-18 2017-08-24 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
JP6137834B2 (ja) 2010-02-24 2017-05-31 アローヘッド ファーマシューティカルズ インコーポレイテッド siRNAの標的化送達のための組成物
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
WO2012083046A2 (en) * 2010-12-17 2012-06-21 Arrowhead Research Corporation Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
AU2011352204B2 (en) 2010-12-29 2015-05-21 Arrowhead Pharmaceuticals, Inc. In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
KR20140051357A (ko) 2011-08-26 2014-04-30 애로우헤드 리서치 코오포레이션 In Vivo 핵산 전달용 폴리(비닐 에스테르) 고분자
IN2014CN03463A (es) * 2011-11-18 2015-10-09 Alnylam Pharmaceuticals Inc
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
KR20190084354A (ko) 2012-05-24 2019-07-16 아이오니스 파마수티컬즈, 인코포레이티드 아포지질단백질 (a) 발현을 조절하는 방법들 및 조성물들
NZ631552A (en) * 2013-05-01 2017-02-24 Ionis Pharmaceuticals Inc Compositions and methods for modulating hbv expression
WO2016149020A1 (en) * 2015-03-17 2016-09-22 Arrowhead Research Corporation Rna interference agents
US9976141B2 (en) 2015-05-29 2018-05-22 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of Hif2alpha
MA43335B1 (fr) * 2015-07-31 2021-01-29 Alnylam Pharmaceuticals Inc Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
TWI783434B (zh) 2016-03-07 2022-11-11 美商愛羅海德製藥公司 治療性化合物之標靶性配體

Also Published As

Publication number Publication date
US20170096665A1 (en) 2017-04-06
IL290566B1 (en) 2023-03-01
AU2016331084A1 (en) 2018-04-19
MX2022013010A (es) 2022-11-09
UA121998C2 (uk) 2020-08-25
PT3356529T (pt) 2021-11-04
EP3356529A2 (en) 2018-08-08
PE20181139A1 (es) 2018-07-17
EP3356529A4 (en) 2019-09-04
RS62523B1 (sr) 2021-11-30
US10662427B2 (en) 2020-05-26
WO2017059223A9 (en) 2017-08-17
JOP20210043A1 (ar) 2017-06-16
KR20180052703A (ko) 2018-05-18
TW201726918A (zh) 2017-08-01
DK3356529T3 (da) 2021-11-08
JP7442574B2 (ja) 2024-03-04
HK1259063A1 (zh) 2019-11-22
CO2018003678A2 (es) 2018-11-30
UY36926A (es) 2017-04-28
JP2021087459A (ja) 2021-06-10
CN108368506A (zh) 2018-08-03
US20200263179A1 (en) 2020-08-20
PH12018500713A1 (en) 2018-10-15
CY1125263T1 (el) 2023-03-24
EP4029941A1 (en) 2022-07-20
JP7116212B2 (ja) 2022-08-09
MY195796A (en) 2023-02-21
CA3000397A1 (en) 2017-04-06
TWI836693B (zh) 2024-03-21
ES2896298T3 (es) 2022-02-24
WO2017059223A3 (en) 2017-05-11
IL290566B2 (en) 2023-07-01
EP3356529B1 (en) 2021-08-25
LT3356529T (lt) 2021-12-27
IL300438A (en) 2023-04-01
JOP20160211B1 (ar) 2021-08-17
MA43347B1 (fr) 2021-11-30
JP2022113835A (ja) 2022-08-04
US20180195070A1 (en) 2018-07-12
ZA202106265B (en) 2023-08-30
MX2018003833A (es) 2018-06-18
AU2016331084B2 (en) 2022-09-08
IL258333A (en) 2018-05-31
JP6991966B2 (ja) 2022-02-03
TWI784934B (zh) 2022-12-01
US9932586B2 (en) 2018-04-03
EA201890864A1 (ru) 2018-09-28
JP2024009262A (ja) 2024-01-19
SI3356529T1 (sl) 2022-01-31
MA43347A (fr) 2018-08-08
IL258333B (en) 2022-03-01
BR112018006489A2 (pt) 2018-10-09
TN2018000094A1 (en) 2019-07-08
WO2017059223A2 (en) 2017-04-06
IL290566A (en) 2022-04-01
HUE055942T2 (hu) 2022-01-28
CL2018000803A1 (es) 2018-08-31
SG10202008530TA (en) 2020-10-29
EA038478B1 (ru) 2021-09-03
HRP20211410T1 (hr) 2021-12-24
JP2018529732A (ja) 2018-10-11
PL3356529T3 (pl) 2021-12-20
AU2022283623A1 (en) 2023-02-02
TW202332769A (zh) 2023-08-16
NZ741086A (en) 2023-11-24

Similar Documents

Publication Publication Date Title
CO2018003678A2 (es) Composiciones y métodos para inhibir la expresión génica de lpa
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP20017905A (es) AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3)
CO2020001740A2 (es) Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
UY37098A (es) Moduladores de ror-gamma
MA43377A (fr) Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
CR20160237A (es) Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20150604A (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
CO2018002198A2 (es) Composiciones farmacéuticas que comprenden un compuesto oligomérico para modular la expresión de apolipoproteína (a)
CR20180298A (es) Nuevos derivados de fenilo
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
AR106227A1 (es) COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN GÉNICA DEL GEN DE LA APOLIPOPROTEÍNA APO(a) (LPA)
DOP2014000221A (es) Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek
AR112754A1 (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO
AR113014A1 (es) AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3)
AR113454A1 (es) AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1
AR113254A1 (es) AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA ANGIOPOYETINA TIPO 3 (ANGPTL3) Y MÉTODOS DE USO
AR105611A1 (es) TERAPIA ARNi PARA INFECCIÓN POR VIRUS DE HEPATITIS B
AR096390A1 (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
AR090580A1 (es) Composiciones farmaceuticas para terapia combinada